Date: 2011-03-24
Type of information: Plant acquisition
Acquired company: Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA)
Acquiring company: Boehringer Ingelheim (Germany)
Amount: undisclosed
Terms: Boehringer Ingelheim has formally acquired Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California (USA). This acquisition involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site. The state-of-the-art facility currently employs more than 300 employees and consists of more than 200,000 square feet for laboratories, manufacturing and process development suitable for clinical and market supplies. The purchase agreement was signed in January 2011. The companies agreed not to disclose details of the purchase price. Boehringer Ingelheim has been a contract manufacturer for Amgen for ten years and will continue to support Amgen’s delivery of safe and effective medicines to patients around the world. The Boehringer Ingelheim contract manufacturing portfolio includes sixteen licensed biopharmaceuticals manufactured in globally licensed multi-product facilities, a growing pipeline of New Biological Entities (NBEs), and a growth strategy in the Contract Manufacturing Business (CMB). Boehringer Ingelheim’s objective is to remain a leader in Contract Manufacturing as an industry benchmark for operational excellence including technical expertise and state-of-the-art technology.
Details:
Related: Production
Manufacturing
